We are monitoring the impact of COVID-19 & Recession alarm on Europe Cancer Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Share on

Europe Cancer Monoclonal Antibodies Market Research Report – Segmented By Application, Type, Conjugated Cancer Therapies & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 158
Pages: 120

Europe Cancer Monoclonal Antibodies Market Size (2022 to 2027)

The size of the Cancer Monoclonal Antibodies Market in Europe was valued at USD 15.65 billion in 2022. It is further estimated to grow and worth USD 26.25 billion by 2027, registering a growth rate of 10.9% between 2022 to 2027.

Rising prevalence for the targeted therapeutic procedures is a key driving factor for the market to grow extensively. Increasing incidences of chronic diseases is another common attribute for the market to grow in Europe. Besides, escalating expenditure on healthcare is lavishing the growth rate of the cancer monoclonal antibodies market. Growing awareness over the development of innovative drugs is greatly influencing the demand of the market. As cancer is being the main cause of the number of deaths, the demand for treatment of cancer with monoclonal antibodies is leveraging the growth rate of the market. The rising scale of research centers is also promoting the demand for this market.

However, stringent rules and regulations by the government in approving new products are straightly hindering the growth rate of the market. Fluctuations in the availability of raw materials and increasing prices of final products are slowly restricting the growth rate of the market. Lack of skilled professionals in manufacturing drugs with the latest technology remains a challenging factor for the market.

Changes in government schemes and the launch of reimbursement policies in favor of the common people are anticipated to present growth opportunities for the market. An increasing number of healthcare centers are also factors accelerating the demand of the European cancer monoclonal antibodies market. Growing awareness over the availability of various diagnostic and treatment procedures is greatly influencing the demand of the market.

This research report on the European Cancer Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories:

By Application: 

  • Liver
  • Breast
  • Blood
  • Brain
  • Hodgkin’s And Non-Hodgkin’s Lymphoma
  • Colorectal
  • Leukemia
  • Others

By Type: 

  • Murine Antibodies
  • Chimeric & Humanised Antibodies
  • Fully Humanized Antibodies

By Conjugated Cancer Therapies: 

  • Immunoliposome
  • Radioimmunotherapy
  • ADEPT
  • Immunocytokines
  • Others

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the cancer monoclonal antibodies market in Europe has a tremendous growth rate from the past few years. The United Kingdom is leading with the largest shares of the market with the increasing economic status. Italy and Germany are next to the United Kingdom in holding the highest shares due to adopting the latest technological developments in the medical sector. Spain and the Rest of Europe are inclined to have leading shares in the forecast period.

Notable companies leading the European Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis & Spectrum Pharmaceuticals.

  1. Introduction

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods          

                1.4 General Study Assumptions

  1. Research Methodology

                2.1 Introduction               

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

  1. Overview

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 New Developments               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market              

  1. Market Segmentation

                5.1 By Application           

                                5.1.1 Liver

                                5.1.2 Breast

                                5.1.3 Brain

                                5.1.4 Blood

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma

                                5.1.6 Colorectal

                                5.1.7 Leukaemia

                                5.1.8 Others

                5.2 By Type        

                                5.2.1 Murine Antibodies

                                5.2.2 Chimeric and Humanised Antibodies

                                5.2.3 Fully Humanized Antibodies

                5.3 Conjugate Cancer Therapies               

                                5.3.1 Immunoliposome

                                5.3.2 Radioimmunotherapy

                                5.3.3 ADEPT

                                5.3.4 Immunocytokines

                                5.3.5 Others

  1. Geographical Analysis

                6.1 Introduction               

                6.2 U.K 

                6.3 Spain             

                6.4 Germany     

                6.5 Italy               

                6.6 France          

  1. Strategic Analysis

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

  1. Market Leaders' Analysis

                8.1 Roche

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Strategic Evaluation and Operations

                                8.1.4 Financial analysis

                                8.1.5 Legal issues

                                8.1.6 Recent Developments

                                8.1.7 SWOT analysis

                                8.1.8 Analyst View

                8.2 Amgen

                8.3 Genmab

                8.4 Glaxosmithkline

                8.5 Bristol Meyer Squibb

                8.6 Eli Lilly

                8.7 Immunogen

                8.8 Novartis

                8.9 Seattle Genetics

                8.10 Spectrum Pharmaceuticals

  1. Competitive Landscape

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis       

                9.3 Agreements, collaborations and Joint Ventures         

                9.4 New Product Launches         

  1. Expert Opinions

                10.1 Market Outlook     

                10.2 Investment Opportunities 

     Appendix                           

  1. List of Tables
  2. List of Figures
  1. Europe Cancer Monoclonal Antibodies Market, By Region, From 2022 - 2027 (USD Million)
  2. Europe Cancer Monoclonal Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  3. Europe Liver Market, By Region, From 2022 - 2027 (USD Million)
  4. Europe Breast Market, By Region, From 2022 - 2027 (USD Million)
  5. Europe Brain Market, By Region, From 2022 - 2027 (USD Million)
  6. Europe Blood Market, By Region, From 2022 - 2027 (USD Million)
  7. Europe Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2022 - 2027 (USD Million)
  8. Europe Colorectal Market, By Region, From 2022 - 2027 (USD Million)
  9. Europe Leukaemia Market, By Region, From 2022 - 2027 (USD Million)
  10. Europe Others Market, By Region, From 2022 - 2027 (USD Million)
  11. Europe Cancer Monoclonal Antibodies Market, By Type, From 2022 - 2027 (USD Million)
  12. Europe Murine Antibodies Market, By Region, From 2022 - 2027 (USD Million)
  13. Europe Chimeric and Humanised Antibodies Market, By Region, From 2022 - 2027 (USD Million)
  14. Europe Fully Humanized Antibodies Market, By Region, From 2022 - 2027 (USD Million)
  15. Europe Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2022 - 2027 (USD Million)
  16. Europe Immunoliposome Market, By Region, From 2022 - 2027 (USD Million)
  17. Europe Radioimmunotherapy Market, By Region, From 2022 - 2027 (USD Million)
  18. Europe ADEPT Market, By Region, From 2022 - 2027 (USD Million)
  19. Europe Immunocytokines Market, By Region, From 2022 - 2027 (USD Million)
  20. Europe Others Market, By Region, From 2022 - 2027 (USD Million)
  21. Cancer Monoclonal Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  22. Liver Market, By Region, From 2022 - 2027 (USD Million)
  23. Breast Market, By Region, From 2022 - 2027 (USD Million)
  24. Brain Market, By Region, From 2022 - 2027 (USD Million)
  25. Blood Market, By Region, From 2022 - 2027 (USD Million)
  26. Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2022 - 2027 (USD Million)
  27. Colorectal Market, By Region, From 2022 - 2027 (USD Million)
  28. Leukaemia Market, By Region, From 2022 - 2027 (USD Million)
  29. Others Market, By Region, From 2022 - 2027 (USD Million)
  30. U.K. Cancer Monoclonal Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  31. U.K. Cancer Monoclonal Antibodies Market, By Type, From 2022 - 2027 (USD Million)
  32. U.K. Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2022 - 2027 (USD Million)
  33. Germany Cancer Monoclonal Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  34. Germany Cancer Monoclonal Antibodies Market, By Type, From 2022 - 2027 (USD Million)
  35. Germany Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2022 - 2027 (USD Million)
  36. France Cancer Monoclonal Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  37. France Cancer Monoclonal Antibodies Market, By Type, From 2022 - 2027 (USD Million)
  38. France Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2022 - 2027 (USD Million)
  39. Italy Cancer Monoclonal Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  40. Italy Cancer Monoclonal Antibodies Market, By Type, From 2022 - 2027 (USD Million)
  41. Italy Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2022 - 2027 (USD Million)
  42. Spain Cancer Monoclonal Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  43. Spain Cancer Monoclonal Antibodies Market, By Type, From 2022 - 2027 (USD Million)
  44. Spain Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample